Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1878 5
1879 1
1883 1
1885 1
1889 1
1890 1
1901 1
1908 2
1909 1
1910 1
1912 2
1913 1
1915 2
1918 1
1920 1
1921 2
1923 1
1927 3
1937 1
1939 1
1946 2
1947 4
1948 2
1949 3
1950 4
1951 4
1952 6
1953 6
1954 6
1955 3
1956 3
1958 5
1959 2
1960 6
1961 5
1962 11
1963 18
1964 17
1965 9
1966 14
1967 22
1968 24
1969 24
1970 21
1971 26
1972 24
1973 36
1974 14
1975 27
1976 29
1977 16
1978 29
1979 28
1980 12
1981 19
1982 14
1983 10
1984 16
1985 31
1986 22
1987 20
1988 18
1989 22
1990 14
1991 19
1992 31
1993 25
1994 22
1995 28
1996 32
1997 26
1998 36
1999 44
2000 46
2001 50
2002 41
2003 28
2004 40
2005 42
2006 37
2007 34
2008 43
2009 24
2010 35
2011 37
2012 53
2013 34
2014 31
2015 37
2016 32
2017 30
2018 34
2019 38
2020 36
2021 37
2022 43
2023 52
2024 44
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,822 results

Results by year

Filters applied: . Clear all
Page 1
A Clinical Update on Gestational Diabetes Mellitus.
Sweeting A, Wong J, Murphy HR, Ross GP. Sweeting A, et al. Among authors: ross gp. Endocr Rev. 2022 Sep 26;43(5):763-793. doi: 10.1210/endrev/bnac003. Endocr Rev. 2022. PMID: 35041752 Free PMC article.
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Schneeweiss A, et al. Among authors: ross g. Ann Oncol. 2013 Sep;24(9):2278-84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22. Ann Oncol. 2013. PMID: 23704196 Free article. Clinical Trial.
Rotenone, paraquat, and Parkinson's disease.
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Tanner CM, et al. Among authors: ross gw. Environ Health Perspect. 2011 Jun;119(6):866-72. doi: 10.1289/ehp.1002839. Epub 2011 Jan 26. Environ Health Perspect. 2011. PMID: 21269927 Free PMC article.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Gianni L, et al. Among authors: ross g. Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6. Lancet Oncol. 2012. PMID: 22153890 Clinical Trial.
Porphyria.
Sood S, Mingos N, Ross G. Sood S, et al. Among authors: ross g. N Engl J Med. 2017 Nov 23;377(21):2100. doi: 10.1056/NEJMc1712682. N Engl J Med. 2017. PMID: 29182251 No abstract available.
Acute elbow dislocations.
Kuhn MA, Ross G. Kuhn MA, et al. Among authors: ross g. Orthop Clin North Am. 2008 Apr;39(2):155-61, v. doi: 10.1016/j.ocl.2007.12.004. Orthop Clin North Am. 2008. PMID: 18374806 Review.
Missed Directives.
Ross GS. Ross GS. Ann Intern Med. 2023 Apr;176(4):580-581. doi: 10.7326/M22-3199. Ann Intern Med. 2023. PMID: 37068298 No abstract available.
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortún J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Solé A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Brüggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC. Maertens JA, et al. Among authors: ross gg. Lancet Infect Dis. 2025 Jun 17:S1473-3099(25)00224-5. doi: 10.1016/S1473-3099(25)00224-5. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40541222
1,822 results